Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New diabetes shot GZR18 takes on semaglutide in major trial

NCT ID NCT06778967

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tests a new injectable drug called GZR18 in about 1,100 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by metformin or other oral medications. Participants receive either GZR18 or the approved drug semaglutide to compare how well each lowers blood sugar and affects weight. The goal is to see if GZR18 is a safe and effective new treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GZR18 injection (a drug similar to semaglutide, given as a shot under the skin)
What this could lead to
If it works, this could offer a new once-weekly injection option to help people with type 2 diabetes lower blood sugar and possibly lose weight.
What could go wrong
This is a phase 3 trial, but it only includes Chinese participants, so results may not apply to other groups. GZR18 is new and may cause side effects like nausea or vomiting, common with this class of drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * T2DM is diagnosed for at least 12 weeks according to the diagnostic criteria of diabetes mellitus issued by the World Health Organization (WHO) in 1999 and the supplementary diagnostic criteria of WHO in 2011 (HbA1c diagnosis is recommended). * Antidiabetic drugs that meet any of the following within 8 weeks before screening: * A stable dose of metformin hydrochloride monotherapy at a dose of ≥ 1500 mg/day or the maximum tolerated dose ; * A stable dose of metformin (≥ 1500 mg/day or the maximum tolerated dose ) in combination with SGLT2 inhibitors; * A stable dose of metformin (≥1500 mg/day or a maximum tolerated dose \< 1500 but ≥ 1000 mg/day) in combination with a stable daily dose of sulfonylureas. * HbA1c ≥ 7.5% and ≤ 11% at screening (central laboratory). * BG \< 15 mmol/L at screening (central laboratory). Exclusion Criteria: * Type 1 diabetes mellitus or special type of diabetes mellitus. * Diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar state within 6 months before screening, or diabetic ketosis at screening/before randomization. * Severe chronic complications of diabetes (such as proliferative retinopathy or maculopathy, diabetic painful neuropathy, intermittent claudication, or diabetic foot) at screening or before randomization. * History of acute or chronic pancreatitis and pancreatic injury before screening. * History or relevant family history of medullary thyroid cancer, multiple endocrine neoplasia (MEN) 2A or 2B before screening. * Any laboratory test indicator meeting the following criteria at screening or before randomization: * Calcitonin level ≥ 50 ng/L (pg/mL) at screening. * ALT ≥ 3.0 × upper limit of normal (ULN) or AST ≥ 3.0 × ULN or total bilirubin ≥ 2.0 × ULN. * Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2, calculated using CKD-EPI equation (see Appendix 3). * Fasting triglyceride (TG) ≥ 5.7 mmol/L or 500 mg/dL. * Blood amylase or lipase \> 1.5 × ULN. * Hemoglobin ≤ 100 g/L for women and ≤ 110 g/L for men.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tianjin Medical University General Hospital

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.